Target to Pay $3M to Resolve Massachusetts Medicaid Claim - NBC10 Boston

Target to Pay $3M to Resolve Massachusetts Medicaid Claim

Target Corp. has agreed to pay $3 million to resolve allegations that it violated rules of Massachusetts' Medicaid program

Find NBC Boston in your area

Channel 10 on most providers

Channel 15, 60 and 8 Over the Air

    processing...

    NEWSLETTERS

    Target to Pay $3M to Resolve Massachusetts Medicaid Claim
    Getty Images
    FILE

    Target Corp. has agreed to pay $3 million to resolve allegations that it violated rules of Massachusetts' Medicaid program.

    Federal and Massachusetts authorities allege Minneapolis-based Target violated federal and state False Claims Acts by automatically refilling Medicaid recipients' prescriptions and seeking payment from Medicaid.

    Massachusetts is among several states that prohibit pharmacies from automatically refilling Medicaid prescriptions without the beneficiary's explicit request. The policy is designed to prevent unnecessary prescriptions from being reimbursed by taxpayers.

    Authorities say Target pharmacies knowingly and routinely enrolled MassHealth beneficiaries in the auto-refill program, then billed MassHealth. The practice continued until Target sold its pharmacy business to CVS Health in 2015.

    Death Toll, Damages Climb From Typhoon Hagibis

    [NATL] Death Toll, Damages Climb From Typhoon Hagibis

    The death toll from Typhoon Hagibis climbed to 53 on Tuesday, days after it tore through Japan and left hundreds of thousands of homes wrecked, flooded or out of power. Hagibis caused more than 200 rivers to overflow when it hit the island nation on Saturday.

    (Published Tuesday, Oct. 15, 2019)

    Target says it cooperated and provided information to authorities, including information about its efforts to comply with Medicaid laws. Target says it's satisfied the issue is resolved.

    Authorities say the company denied wrongdoing.


    Get the latest from NBC Boston anywhere, anytime:

    App

    Download our FREE app for iPhone, iPad and Android. You can also follow us on Facebook, Twitter and Instagram, and sign up for our e-mail newsletters.